OptiNose, Inc. (NASDAQ: OPTN) Stock Competitors & Peer Comparison
See OPTN's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for OPTN and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| OPTN | $9.60 | +0.00% | 97.2M | -4.42 | -$2.17 | N/A |
| TAK | $19.67 | +1.13% | 62.2B | 14.16 | $1.39 | +3.59% |
| TEVA | $41.50 | +0.95% | 48.3B | 14.16 | $2.93 | N/A |
| HLN | $10.13 | +1.91% | 44.5B | 20.71 | $0.49 | +1.96% |
| ZTS | $79.38 | +1.22% | 32.8B | 12.06 | $6.58 | +2.65% |
| VTRS | $18.66 | +2.41% | 21.4B | 7.40 | $2.52 | +2.60% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $23.55 | +0.04% | 11.8B | 22.23 | $1.06 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $13.07 | +1.32% | 10.9B | 27.79 | $0.47 | +0.64% |
Stock Comparison
Takeda Pharmaceutical Company Limited (NYSE: TAK)
OPTN vs TAK Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, TAK has a market cap of 62.2B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while TAK trades at $19.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas TAK's P/E ratio is 14.16. In terms of profitability, OPTN's ROE is +0.34%, compared to TAK's ROE of +0.02%. Regarding short-term risk, OPTN is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check TAK's competition here
Teva Pharmaceutical Industries Limited (NYSE: TEVA)
OPTN vs TEVA Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, TEVA has a market cap of 48.3B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while TEVA trades at $41.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas TEVA's P/E ratio is 14.16. In terms of profitability, OPTN's ROE is +0.34%, compared to TEVA's ROE of +0.09%. Regarding short-term risk, OPTN is less volatile compared to TEVA. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check TEVA's competition here
Haleon plc (NYSE: HLN)
OPTN vs HLN Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while HLN trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas HLN's P/E ratio is 20.71. In terms of profitability, OPTN's ROE is +0.34%, compared to HLN's ROE of +0.10%. Regarding short-term risk, OPTN is less volatile compared to HLN. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check HLN's competition here
Zoetis Inc. (NYSE: ZTS)
OPTN vs ZTS Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ZTS has a market cap of 32.8B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ZTS trades at $79.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ZTS's P/E ratio is 12.06. In terms of profitability, OPTN's ROE is +0.34%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, OPTN is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ZTS's competition here
Viatris Inc. (NASDAQ: VTRS)
OPTN vs VTRS Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, VTRS has a market cap of 21.4B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while VTRS trades at $18.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas VTRS's P/E ratio is 7.40. In terms of profitability, OPTN's ROE is +0.34%, compared to VTRS's ROE of -0.03%. Regarding short-term risk, OPTN is less volatile compared to VTRS. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check VTRS's competition here
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)
OPTN vs ITCI Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ITCI's P/E ratio is -180.64. In terms of profitability, OPTN's ROE is +0.34%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, OPTN is similarly volatile compared to ITCI. This indicates similar risk in terms of short-term price fluctuations for OPTN.Check ITCI's competition here
Elanco Animal Health Incorporated (NYSE: ELAN)
OPTN vs ELAN Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ELAN has a market cap of 11.8B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ELAN trades at $23.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ELAN's P/E ratio is 22.23. In terms of profitability, OPTN's ROE is +0.34%, compared to ELAN's ROE of -0.03%. Regarding short-term risk, OPTN is less volatile compared to ELAN. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ELAN's competition here
Catalent, Inc. (NYSE: CTLT)
OPTN vs CTLT Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas CTLT's P/E ratio is -27.84. In terms of profitability, OPTN's ROE is +0.34%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, OPTN is less volatile compared to CTLT. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check CTLT's competition here
Dr. Reddy's Laboratories Limited (NYSE: RDY)
OPTN vs RDY Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, RDY has a market cap of 10.9B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while RDY trades at $13.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas RDY's P/E ratio is 27.79. In terms of profitability, OPTN's ROE is +0.34%, compared to RDY's ROE of +0.09%. Regarding short-term risk, OPTN is less volatile compared to RDY. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check RDY's competition here
Alkermes plc (NASDAQ: ALKS)
OPTN vs ALKS Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ALKS has a market cap of 6.9B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ALKS trades at $41.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ALKS's P/E ratio is 43.39. In terms of profitability, OPTN's ROE is +0.34%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, OPTN is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ALKS's competition here
Lantheus Holdings, Inc. (NASDAQ: LNTH)
OPTN vs LNTH Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, LNTH has a market cap of 6.5B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while LNTH trades at $99.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas LNTH's P/E ratio is 16.76. In terms of profitability, OPTN's ROE is +0.34%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, OPTN is less volatile compared to LNTH. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check LNTH's competition here
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX)
OPTN vs AMRX Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, AMRX has a market cap of 6.1B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while AMRX trades at $19.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas AMRX's P/E ratio is 21.31. In terms of profitability, OPTN's ROE is +0.34%, compared to AMRX's ROE of -3.27%. Regarding short-term risk, OPTN is less volatile compared to AMRX. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check AMRX's competition here
Regencell Bioscience Holdings Limited (NASDAQ: RGC)
OPTN vs RGC Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, RGC has a market cap of 4.8B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while RGC trades at $9.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas RGC's P/E ratio is -959.00. In terms of profitability, OPTN's ROE is +0.34%, compared to RGC's ROE of -1.61%. Regarding short-term risk, OPTN is less volatile compared to RGC. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check RGC's competition here
Indivior Pharmaceuticals Inc (NASDAQ: INDV)
OPTN vs INDV Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, INDV has a market cap of 4B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while INDV trades at $32.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas INDV's P/E ratio is 8.89. In terms of profitability, OPTN's ROE is +0.34%, compared to INDV's ROE of -2.16%. Regarding short-term risk, OPTN is less volatile compared to INDV. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check INDV's competition here
HUTCHMED (China) Limited (NASDAQ: HCM)
OPTN vs HCM Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, HCM has a market cap of 2.5B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while HCM trades at $14.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas HCM's P/E ratio is 135.88. In terms of profitability, OPTN's ROE is +0.34%, compared to HCM's ROE of +0.01%. Regarding short-term risk, OPTN is less volatile compared to HCM. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check HCM's competition here
Alvotech (NASDAQ: ALVOW)
OPTN vs ALVOW Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ALVOW trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ALVOW's P/E ratio is 37.90. In terms of profitability, OPTN's ROE is +0.34%, compared to ALVOW's ROE of +0.77%. Regarding short-term risk, OPTN is similarly volatile compared to ALVOW. This indicates similar risk in terms of short-term price fluctuations for OPTN.Check ALVOW's competition here
Bausch Health Companies Inc. (NYSE: BHC)
OPTN vs BHC Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, BHC has a market cap of 2.4B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while BHC trades at $6.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas BHC's P/E ratio is 1.60. In terms of profitability, OPTN's ROE is +0.34%, compared to BHC's ROE of +0.89%. Regarding short-term risk, OPTN is less volatile compared to BHC. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check BHC's competition here
Perrigo Company plc (NYSE: PRGO)
OPTN vs PRGO Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, PRGO has a market cap of 2.3B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while PRGO trades at $16.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas PRGO's P/E ratio is 6.65. In terms of profitability, OPTN's ROE is +0.34%, compared to PRGO's ROE of -0.56%. Regarding short-term risk, OPTN is less volatile compared to PRGO. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check PRGO's competition here
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH)
OPTN vs DCPH Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas DCPH's P/E ratio is -11.58. In terms of profitability, OPTN's ROE is +0.34%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, OPTN is less volatile compared to DCPH. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check DCPH's competition here
Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN)
OPTN vs SUPN Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, SUPN has a market cap of 2.2B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while SUPN trades at $37.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas SUPN's P/E ratio is 12.38. In terms of profitability, OPTN's ROE is +0.34%, compared to SUPN's ROE of -0.10%. Regarding short-term risk, OPTN is less volatile compared to SUPN. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check SUPN's competition here
Avadel Pharmaceuticals plc (NASDAQ: AVDL)
OPTN vs AVDL Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, OPTN's ROE is +0.34%, compared to AVDL's ROE of +0.10%. Regarding short-term risk, OPTN is similarly volatile compared to AVDL. This indicates similar risk in terms of short-term price fluctuations for OPTN.Check AVDL's competition here
Embecta Corp. (NASDAQ: EMBCV)
OPTN vs EMBCV Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas EMBCV's P/E ratio is N/A. In terms of profitability, OPTN's ROE is +0.34%, compared to EMBCV's ROE of -0.19%. Regarding short-term risk, OPTN is less volatile compared to EMBCV. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check EMBCV's competition here
Dynavax Technologies Corporation (NASDAQ: DVAX)
OPTN vs DVAX Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas DVAX's P/E ratio is -41.89. In terms of profitability, OPTN's ROE is +0.34%, compared to DVAX's ROE of +0.09%. Regarding short-term risk, OPTN is similarly volatile compared to DVAX. This indicates similar risk in terms of short-term price fluctuations for OPTN.Check DVAX's competition here
Alvotech (NASDAQ: ALVO)
OPTN vs ALVO Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ALVO has a market cap of 1.8B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ALVO trades at $5.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ALVO's P/E ratio is -8.47. In terms of profitability, OPTN's ROE is +0.34%, compared to ALVO's ROE of +0.77%. Regarding short-term risk, OPTN is less volatile compared to ALVO. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ALVO's competition here
Trulieve Cannabis Corp. (NYSE: TRLV)
OPTN vs TRLV Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, TRLV has a market cap of 1.7B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while TRLV trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas TRLV's P/E ratio is -4.07. In terms of profitability, OPTN's ROE is +0.34%, compared to TRLV's ROE of -0.44%. Regarding short-term risk, OPTN is less volatile compared to TRLV. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check TRLV's competition here
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP)
OPTN vs ANIP Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ANIP has a market cap of 1.7B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ANIP trades at $72.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ANIP's P/E ratio is 8.79. In terms of profitability, OPTN's ROE is +0.34%, compared to ANIP's ROE of +0.19%. Regarding short-term risk, OPTN is less volatile compared to ANIP. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ANIP's competition here
Taro Pharmaceutical Industries Ltd. (NYSE: TARO)
OPTN vs TARO Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas TARO's P/E ratio is 30.05. In terms of profitability, OPTN's ROE is +0.34%, compared to TARO's ROE of +0.03%. Regarding short-term risk, OPTN is less volatile compared to TARO. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check TARO's competition here
Phibro Animal Health Corporation (NASDAQ: PAHC)
OPTN vs PAHC Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, PAHC has a market cap of 1.6B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while PAHC trades at $38.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas PAHC's P/E ratio is 13.25. In terms of profitability, OPTN's ROE is +0.34%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, OPTN is less volatile compared to PAHC. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check PAHC's competition here
Pacira BioSciences, Inc. (NASDAQ: PCRX)
OPTN vs PCRX Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, PCRX has a market cap of 1.4B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while PCRX trades at $36.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas PCRX's P/E ratio is 13.98. In terms of profitability, OPTN's ROE is +0.34%, compared to PCRX's ROE of +0.02%. Regarding short-term risk, OPTN is less volatile compared to PCRX. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check PCRX's competition here
Eton Pharmaceuticals, Inc. (NASDAQ: ETON)
OPTN vs ETON Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ETON has a market cap of 1.4B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ETON trades at $50.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ETON's P/E ratio is 132.34. In terms of profitability, OPTN's ROE is +0.34%, compared to ETON's ROE of +0.40%. Regarding short-term risk, OPTN is less volatile compared to ETON. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ETON's competition here
Cronos Group Inc. (NASDAQ: CRON)
OPTN vs CRON Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, CRON has a market cap of 1.2B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while CRON trades at $3.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas CRON's P/E ratio is 16.44. In terms of profitability, OPTN's ROE is +0.34%, compared to CRON's ROE of +0.06%. Regarding short-term risk, OPTN is less volatile compared to CRON. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check CRON's competition here
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH)
OPTN vs AMPH Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while AMPH trades at $25.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas AMPH's P/E ratio is 8.83. In terms of profitability, OPTN's ROE is +0.34%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, OPTN is less volatile compared to AMPH. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check AMPH's competition here
Harrow Health, Inc. (NASDAQ: HROW)
OPTN vs HROW Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, HROW has a market cap of 1B. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while HROW trades at $27.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas HROW's P/E ratio is -27.56. In terms of profitability, OPTN's ROE is +0.34%, compared to HROW's ROE of -1.04%. Regarding short-term risk, OPTN is less volatile compared to HROW. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check HROW's competition here
PetIQ, Inc. (NASDAQ: PETQ)
OPTN vs PETQ Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas PETQ's P/E ratio is 83.73. In terms of profitability, OPTN's ROE is +0.34%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, OPTN is less volatile compared to PETQ. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check PETQ's competition here
Collegium Pharmaceutical, Inc. (NASDAQ: COLL)
OPTN vs COLL Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, COLL has a market cap of 755M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while COLL trades at $23.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas COLL's P/E ratio is 2.91. In terms of profitability, OPTN's ROE is +0.34%, compared to COLL's ROE of +0.16%. Regarding short-term risk, OPTN is less volatile compared to COLL. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check COLL's competition here
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD)
OPTN vs IRWD Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, IRWD has a market cap of 578.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while IRWD trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas IRWD's P/E ratio is 4.49. In terms of profitability, OPTN's ROE is +0.34%, compared to IRWD's ROE of -0.57%. Regarding short-term risk, OPTN is less volatile compared to IRWD. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check IRWD's competition here
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
OPTN vs BDSI Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas BDSI's P/E ratio is 6.82. In terms of profitability, OPTN's ROE is +0.34%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, OPTN is less volatile compared to BDSI. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check BDSI's competition here
Evotec SE (NASDAQ: EVO)
OPTN vs EVO Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, EVO has a market cap of 491.9M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while EVO trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas EVO's P/E ratio is -1.96. In terms of profitability, OPTN's ROE is +0.34%, compared to EVO's ROE of -0.27%. Regarding short-term risk, OPTN is less volatile compared to EVO. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check EVO's competition here
Aquestive Therapeutics, Inc. (NASDAQ: AQST)
OPTN vs AQST Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, AQST has a market cap of 473.8M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while AQST trades at $3.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas AQST's P/E ratio is -5.81. In terms of profitability, OPTN's ROE is +0.34%, compared to AQST's ROE of +2.44%. Regarding short-term risk, OPTN is less volatile compared to AQST. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check AQST's competition here
Evolus, Inc. (NASDAQ: EOLS)
OPTN vs EOLS Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, EOLS has a market cap of 468.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while EOLS trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas EOLS's P/E ratio is -22.45. In terms of profitability, OPTN's ROE is +0.34%, compared to EOLS's ROE of +1.23%. Regarding short-term risk, OPTN is less volatile compared to EOLS. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check EOLS's competition here
Kamada Ltd. (NASDAQ: KMDA)
OPTN vs KMDA Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, KMDA has a market cap of 446.6M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while KMDA trades at $7.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas KMDA's P/E ratio is 20.37. In terms of profitability, OPTN's ROE is +0.34%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, OPTN is less volatile compared to KMDA. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check KMDA's competition here
Alpha Teknova, Inc. (NASDAQ: TKNO)
OPTN vs TKNO Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, TKNO has a market cap of 380.1M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while TKNO trades at $7.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas TKNO's P/E ratio is -22.84. In terms of profitability, OPTN's ROE is +0.34%, compared to TKNO's ROE of -0.25%. Regarding short-term risk, OPTN is less volatile compared to TKNO. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check TKNO's competition here
Tilray Brands, Inc. (NASDAQ: TLRY)
OPTN vs TLRY Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, TLRY has a market cap of 340M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while TLRY trades at $3.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas TLRY's P/E ratio is -2.17. In terms of profitability, OPTN's ROE is +0.34%, compared to TLRY's ROE of -0.09%. Regarding short-term risk, OPTN is less volatile compared to TLRY. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check TLRY's competition here
Emergent BioSolutions Inc. (NYSE: EBS)
OPTN vs EBS Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, EBS has a market cap of 326.9M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while EBS trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas EBS's P/E ratio is 4.43. In terms of profitability, OPTN's ROE is +0.34%, compared to EBS's ROE of -0.36%. Regarding short-term risk, OPTN is less volatile compared to EBS. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check EBS's competition here
Canopy Growth Corporation (NASDAQ: CGC)
OPTN vs CGC Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, CGC has a market cap of 301.7M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while CGC trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas CGC's P/E ratio is -1.60. In terms of profitability, OPTN's ROE is +0.34%, compared to CGC's ROE of -0.33%. Regarding short-term risk, OPTN is less volatile compared to CGC. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check CGC's competition here
Alimera Sciences, Inc. (NASDAQ: ALIM)
OPTN vs ALIM Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ALIM's P/E ratio is 5.28. In terms of profitability, OPTN's ROE is +0.34%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, OPTN is less volatile compared to ALIM. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ALIM's competition here
Glass House Brands Inc (NYSE: GLAS)
OPTN vs GLAS Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, GLAS has a market cap of 279.8M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while GLAS trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas GLAS's P/E ratio is -5.68. In terms of profitability, OPTN's ROE is +0.34%, compared to GLAS's ROE of -0.51%. Regarding short-term risk, OPTN is less volatile compared to GLAS. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check GLAS's competition here
Landec Corporation (NASDAQ: LNDC)
OPTN vs LNDC Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas LNDC's P/E ratio is -4.04. In terms of profitability, OPTN's ROE is +0.34%, compared to LNDC's ROE of +6.44%. Regarding short-term risk, OPTN is less volatile compared to LNDC. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check LNDC's competition here
Aurora Cannabis Inc. (NASDAQ: ACB)
OPTN vs ACB Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ACB has a market cap of 252.6M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ACB trades at $3.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ACB's P/E ratio is -2.88. In terms of profitability, OPTN's ROE is +0.34%, compared to ACB's ROE of -0.21%. Regarding short-term risk, OPTN is less volatile compared to ACB. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ACB's competition here
Lifecore Biomedical, Inc. (NASDAQ: LFCR)
OPTN vs LFCR Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, LFCR has a market cap of 241.8M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while LFCR trades at $6.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas LFCR's P/E ratio is -5.02. In terms of profitability, OPTN's ROE is +0.34%, compared to LFCR's ROE of -3.77%. Regarding short-term risk, OPTN is less volatile compared to LFCR. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check LFCR's competition here
Shineco, Inc. (NASDAQ: TYHT)
OPTN vs TYHT Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas TYHT's P/E ratio is -1.61. In terms of profitability, OPTN's ROE is +0.34%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, OPTN is less volatile compared to TYHT. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check TYHT's competition here
SIGA Technologies, Inc. (NASDAQ: SIGA)
OPTN vs SIGA Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, SIGA has a market cap of 227.8M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while SIGA trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas SIGA's P/E ratio is 11.74. In terms of profitability, OPTN's ROE is +0.34%, compared to SIGA's ROE of -0.02%. Regarding short-term risk, OPTN is less volatile compared to SIGA. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check SIGA's competition here
Recro Pharma, Inc. (NASDAQ: REPH)
OPTN vs REPH Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas REPH's P/E ratio is -8.04. In terms of profitability, OPTN's ROE is +0.34%, compared to REPH's ROE of -0.22%. Regarding short-term risk, OPTN is less volatile compared to REPH. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check REPH's competition here
Theratechnologies Inc. (NASDAQ: THTX)
OPTN vs THTX Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas THTX's P/E ratio is -28.83. In terms of profitability, OPTN's ROE is +0.34%, compared to THTX's ROE of +0.36%. Regarding short-term risk, OPTN is less volatile compared to THTX. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check THTX's competition here
Assertio Holdings, Inc. (NASDAQ: ASRT)
OPTN vs ASRT Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ASRT's P/E ratio is -7.10. In terms of profitability, OPTN's ROE is +0.34%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, OPTN is less volatile compared to ASRT. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ASRT's competition here
Journey Medical Corporation (NASDAQ: DERM)
OPTN vs DERM Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, DERM has a market cap of 139.9M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while DERM trades at $4.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas DERM's P/E ratio is -22.52. In terms of profitability, OPTN's ROE is +0.34%, compared to DERM's ROE of -0.20%. Regarding short-term risk, OPTN is less volatile compared to DERM. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check DERM's competition here
Cardiol Therapeutics Inc. (NASDAQ: CRDL)
OPTN vs CRDL Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, CRDL has a market cap of 132.7M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while CRDL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas CRDL's P/E ratio is -4.38. In terms of profitability, OPTN's ROE is +0.34%, compared to CRDL's ROE of -1.94%. Regarding short-term risk, OPTN is less volatile compared to CRDL. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check CRDL's competition here
Organigram Global Inc. (NASDAQ: OGI)
OPTN vs OGI Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, OGI has a market cap of 130.9M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while OGI trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas OGI's P/E ratio is 2.09. In terms of profitability, OPTN's ROE is +0.34%, compared to OGI's ROE of +0.21%. Regarding short-term risk, OPTN is less volatile compared to OGI. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check OGI's competition here
Organogenesis Holdings Inc. (NASDAQ: ORGO)
OPTN vs ORGO Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ORGO has a market cap of 128.6M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ORGO trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ORGO's P/E ratio is 33.32. In terms of profitability, OPTN's ROE is +0.34%, compared to ORGO's ROE of -0.24%. Regarding short-term risk, OPTN is less volatile compared to ORGO. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ORGO's competition here
Societal CDMO, Inc. (NASDAQ: SCTL)
OPTN vs SCTL Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas SCTL's P/E ratio is -7.86. In terms of profitability, OPTN's ROE is +0.34%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, OPTN is less volatile compared to SCTL. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check SCTL's competition here
BGM Group Ltd. (NASDAQ: BGM)
OPTN vs BGM Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, BGM has a market cap of 110.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while BGM trades at $8.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas BGM's P/E ratio is -1.81. In terms of profitability, OPTN's ROE is +0.34%, compared to BGM's ROE of -0.05%. Regarding short-term risk, OPTN is less volatile compared to BGM. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check BGM's competition here
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX)
OPTN vs CPIX Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, CPIX has a market cap of 107.6M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while CPIX trades at $7.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas CPIX's P/E ratio is -17.95. In terms of profitability, OPTN's ROE is +0.34%, compared to CPIX's ROE of -0.47%. Regarding short-term risk, OPTN is less volatile compared to CPIX. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check CPIX's competition here
Procaps Group S.A. (NASDAQ: PROC)
OPTN vs PROC Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas PROC's P/E ratio is 1.53. In terms of profitability, OPTN's ROE is +0.34%, compared to PROC's ROE of -2.22%. Regarding short-term risk, OPTN is similarly volatile compared to PROC. This indicates similar risk in terms of short-term price fluctuations for OPTN.Check PROC's competition here
Zomedica Corp. (AMEX: ZOM)
OPTN vs ZOM Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ZOM's P/E ratio is -1.62. In terms of profitability, OPTN's ROE is +0.34%, compared to ZOM's ROE of -0.17%. Regarding short-term risk, OPTN is less volatile compared to ZOM. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ZOM's competition here
Upexi, Inc. (NASDAQ: GRVI)
OPTN vs GRVI Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas GRVI's P/E ratio is 26.05. In terms of profitability, OPTN's ROE is +0.34%, compared to GRVI's ROE of -4.51%. Regarding short-term risk, OPTN is less volatile compared to GRVI. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check GRVI's competition here
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
OPTN vs ZYNE Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, OPTN's ROE is +0.34%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, OPTN is less volatile compared to ZYNE. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ZYNE's competition here
Zhengye Biotechnology Holding Limited (NASDAQ: ZYBT)
OPTN vs ZYBT Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ZYBT has a market cap of 69.2M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ZYBT trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ZYBT's P/E ratio is -7.30. In terms of profitability, OPTN's ROE is +0.34%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, OPTN is less volatile compared to ZYBT. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ZYBT's competition here
Silver Spike Investment Corp. (NASDAQ: SSIC)
OPTN vs SSIC Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas SSIC's P/E ratio is 11.93. In terms of profitability, OPTN's ROE is +0.34%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, OPTN is less volatile compared to SSIC. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check SSIC's competition here
The Valens Company Inc. (NASDAQ: VLNS)
OPTN vs VLNS Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas VLNS's P/E ratio is -1.03. In terms of profitability, OPTN's ROE is +0.34%, compared to VLNS's ROE of N/A. Regarding short-term risk, OPTN is less volatile compared to VLNS. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check VLNS's competition here
DURECT Corporation (NASDAQ: DRRX)
OPTN vs DRRX Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas DRRX's P/E ratio is -4.44. In terms of profitability, OPTN's ROE is +0.34%, compared to DRRX's ROE of -0.70%. Regarding short-term risk, OPTN is similarly volatile compared to DRRX. This indicates similar risk in terms of short-term price fluctuations for OPTN.Check DRRX's competition here
Talphera, Inc. (NASDAQ: TLPH)
OPTN vs TLPH Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, TLPH has a market cap of 56.1M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while TLPH trades at $1.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas TLPH's P/E ratio is -4.00. In terms of profitability, OPTN's ROE is +0.34%, compared to TLPH's ROE of -0.87%. Regarding short-term risk, OPTN is less volatile compared to TLPH. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check TLPH's competition here
InterCure Ltd. (NASDAQ: INCR)
OPTN vs INCR Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, INCR has a market cap of 54.1M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while INCR trades at $4.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas INCR's P/E ratio is -4.81. In terms of profitability, OPTN's ROE is +0.34%, compared to INCR's ROE of -0.09%. Regarding short-term risk, OPTN is less volatile compared to INCR. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check INCR's competition here
Jupiter Wellness, Inc. (NASDAQ: JUPW)
OPTN vs JUPW Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas JUPW's P/E ratio is -2.41. In terms of profitability, OPTN's ROE is +0.34%, compared to JUPW's ROE of -3.04%. Regarding short-term risk, OPTN is less volatile compared to JUPW. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check JUPW's competition here
Qilian International Holding Group Limited (NASDAQ: QLI)
OPTN vs QLI Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas QLI's P/E ratio is -4.92. In terms of profitability, OPTN's ROE is +0.34%, compared to QLI's ROE of -0.16%. Regarding short-term risk, OPTN is similarly volatile compared to QLI. This indicates similar risk in terms of short-term price fluctuations for OPTN.Check QLI's competition here
HEXO Corp. (NASDAQ: HEXO)
OPTN vs HEXO Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas HEXO's P/E ratio is -0.26. In terms of profitability, OPTN's ROE is +0.34%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, OPTN is less volatile compared to HEXO. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check HEXO's competition here
Rockwell Medical, Inc. (NASDAQ: RMTI)
OPTN vs RMTI Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, RMTI has a market cap of 29.9M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while RMTI trades at $7.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas RMTI's P/E ratio is -5.54. In terms of profitability, OPTN's ROE is +0.34%, compared to RMTI's ROE of -0.14%. Regarding short-term risk, OPTN is less volatile compared to RMTI. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check RMTI's competition here
China Pharma Holdings, Inc. (AMEX: CPHI)
OPTN vs CPHI Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, CPHI has a market cap of 29.4M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while CPHI trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas CPHI's P/E ratio is -1.59. In terms of profitability, OPTN's ROE is +0.34%, compared to CPHI's ROE of -0.17%. Regarding short-term risk, OPTN is less volatile compared to CPHI. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check CPHI's competition here
Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ: SHPH)
OPTN vs SHPH Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, SHPH has a market cap of 24.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while SHPH trades at $5.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas SHPH's P/E ratio is -0.24. In terms of profitability, OPTN's ROE is +0.34%, compared to SHPH's ROE of -1.57%. Regarding short-term risk, OPTN is less volatile compared to SHPH. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check SHPH's competition here
Cyclo Therapeutics, Inc. (NASDAQ: CYTH)
OPTN vs CYTH Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas CYTH's P/E ratio is -0.80. In terms of profitability, OPTN's ROE is +0.34%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, OPTN is similarly volatile compared to CYTH. This indicates similar risk in terms of short-term price fluctuations for OPTN.Check CYTH's competition here
Aytu BioPharma, Inc. (NASDAQ: AYTU)
OPTN vs AYTU Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, AYTU has a market cap of 22.1M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while AYTU trades at $2.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas AYTU's P/E ratio is -1.72. In terms of profitability, OPTN's ROE is +0.34%, compared to AYTU's ROE of -0.53%. Regarding short-term risk, OPTN is less volatile compared to AYTU. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check AYTU's competition here
TherapeuticsMD, Inc. (NASDAQ: TXMD)
OPTN vs TXMD Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, TXMD has a market cap of 22M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while TXMD trades at $1.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas TXMD's P/E ratio is 96.79. In terms of profitability, OPTN's ROE is +0.34%, compared to TXMD's ROE of -0.01%. Regarding short-term risk, OPTN is less volatile compared to TXMD. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check TXMD's competition here
Optimi Health Corp. (NASDAQ: OPTH)
OPTN vs OPTH Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, OPTH has a market cap of 19.4M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while OPTH trades at $3.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas OPTH's P/E ratio is -2.17. In terms of profitability, OPTN's ROE is +0.34%, compared to OPTH's ROE of -0.90%. Regarding short-term risk, OPTN is less volatile compared to OPTH. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check OPTH's competition here
Evoke Pharma, Inc. (NASDAQ: EVOK)
OPTN vs EVOK Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas EVOK's P/E ratio is -7.97. In terms of profitability, OPTN's ROE is +0.34%, compared to EVOK's ROE of -0.70%. Regarding short-term risk, OPTN is similarly volatile compared to EVOK. This indicates similar risk in terms of short-term price fluctuations for OPTN.Check EVOK's competition here
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX)
OPTN vs ACRX Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ACRX's P/E ratio is -0.31. In terms of profitability, OPTN's ROE is +0.34%, compared to ACRX's ROE of -0.87%. Regarding short-term risk, OPTN is less volatile compared to ACRX. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ACRX's competition here
Caring Brands, Inc. (NASDAQ: CABR)
OPTN vs CABR Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, CABR has a market cap of 11.2M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while CABR trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas CABR's P/E ratio is -1.58. In terms of profitability, OPTN's ROE is +0.34%, compared to CABR's ROE of -3.86%. Regarding short-term risk, OPTN is less volatile compared to CABR. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check CABR's competition here
Agile Therapeutics, Inc. (NASDAQ: AGRX)
OPTN vs AGRX Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas AGRX's P/E ratio is -0.89. In terms of profitability, OPTN's ROE is +0.34%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, OPTN is less volatile compared to AGRX. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check AGRX's competition here
Neoleukin Therapeutics, Inc. (NASDAQ: NLTX)
OPTN vs NLTX Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas NLTX's P/E ratio is -0.28. In terms of profitability, OPTN's ROE is +0.34%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, OPTN is less volatile compared to NLTX. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check NLTX's competition here
Lannett Company, Inc. (NYSE: LCI)
OPTN vs LCI Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas LCI's P/E ratio is -0.04. In terms of profitability, OPTN's ROE is +0.34%, compared to LCI's ROE of +1.66%. Regarding short-term risk, OPTN is less volatile compared to LCI. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check LCI's competition here
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)
OPTN vs ADMP Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ADMP's P/E ratio is -0.08. In terms of profitability, OPTN's ROE is +0.34%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, OPTN is less volatile compared to ADMP. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check ADMP's competition here
InMed Pharmaceuticals Inc. (NASDAQ: INM)
OPTN vs INM Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, INM has a market cap of 7.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while INM trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas INM's P/E ratio is -0.43. In terms of profitability, OPTN's ROE is +0.34%, compared to INM's ROE of -1.35%. Regarding short-term risk, OPTN is less volatile compared to INM. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check INM's competition here
Sonoma Pharmaceuticals, Inc. (NASDAQ: SNOA)
OPTN vs SNOA Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, SNOA has a market cap of 5.5M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while SNOA trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas SNOA's P/E ratio is -1.04. In terms of profitability, OPTN's ROE is +0.34%, compared to SNOA's ROE of -0.54%. Regarding short-term risk, OPTN is less volatile compared to SNOA. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check SNOA's competition here
Mallinckrodt plc (AMEX: MNK)
OPTN vs MNK Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas MNK's P/E ratio is -0.44. In terms of profitability, OPTN's ROE is +0.34%, compared to MNK's ROE of -0.36%. Regarding short-term risk, OPTN is less volatile compared to MNK. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check MNK's competition here
Flora Growth Corp. (NASDAQ: FLGC)
OPTN vs FLGC Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas FLGC's P/E ratio is -0.19. In terms of profitability, OPTN's ROE is +0.34%, compared to FLGC's ROE of -3.03%. Regarding short-term risk, OPTN is less volatile compared to FLGC. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check FLGC's competition here
Gelteq Limited Ordinary Shares (NASDAQ: GELS)
OPTN vs GELS Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, GELS has a market cap of 4.2M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while GELS trades at $0.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas GELS's P/E ratio is -1.05. In terms of profitability, OPTN's ROE is +0.34%, compared to GELS's ROE of -0.25%. Regarding short-term risk, OPTN is less volatile compared to GELS. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check GELS's competition here
cbdMD, Inc. (AMEX: YCBD)
OPTN vs YCBD Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, YCBD has a market cap of 3.8M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while YCBD trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas YCBD's P/E ratio is -0.84. In terms of profitability, OPTN's ROE is +0.34%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, OPTN is less volatile compared to YCBD. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check YCBD's competition here
Akanda Corp. (NASDAQ: AKAN)
OPTN vs AKAN Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, AKAN has a market cap of 2.9M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while AKAN trades at $1.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas AKAN's P/E ratio is -0.03. In terms of profitability, OPTN's ROE is +0.34%, compared to AKAN's ROE of +3.92%. Regarding short-term risk, OPTN is less volatile compared to AKAN. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check AKAN's competition here
PLx Pharma Inc. (NASDAQ: PLXP)
OPTN vs PLXP Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas PLXP's P/E ratio is -0.22. In terms of profitability, OPTN's ROE is +0.34%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, OPTN is less volatile compared to PLXP. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check PLXP's competition here
Universe Pharmaceuticals Inc. (NASDAQ: UPC)
OPTN vs UPC Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, UPC has a market cap of 2.5M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while UPC trades at $3.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas UPC's P/E ratio is -0.49. In terms of profitability, OPTN's ROE is +0.34%, compared to UPC's ROE of -0.03%. Regarding short-term risk, OPTN is less volatile compared to UPC. This indicates lower risk in terms of short-term price fluctuations for OPTN.Check UPC's competition here
Athenex, Inc. (NASDAQ: ATNX)
OPTN vs ATNX Comparison October 2026
OptiNose, Inc. (NASDAQ: OPTN) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, OPTN stands at 97.2M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, OPTN is priced at $9.60 on the NASDAQ, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
OPTN currently has a P/E ratio of -4.42, whereas ATNX's P/E ratio is -0.02. In terms of profitability, OPTN's ROE is +0.34%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, OPTN is similarly volatile compared to ATNX. This indicates similar risk in terms of short-term price fluctuations for OPTN.Check ATNX's competition here